title: Antihyperglycemic activity of kinsenoside, a high yielding constituent from Anoectochilus roxburghii in streptozotocin diabetic rats.
abstract: Different doses of kinsenoside, a high yielding constituent from Anoectochilus roxburghii, was orally administered to further investigate its biological activity and pharmacological mechanisms that involve in the hypoglycemic effect on streptozotocin (STZ) diabetic rats. Our study showed that this compound exhibited significantly antihyperglycemic activity at the dose of 15mg/kg body weight, which is speculated to be partially attributed to modulating the activity of enzymatic antioxidants, scavenging free radicals, and reducing the content of factor NO. Much more intact beta cells in the islets of Langerhans with denser insulin in kinsenoside-treated groups than the negative control were observed, which greatly supported the morphological and functional elucidation. These results displayed that kinsenoside could be useful for repairing beta cells in pancreatic islet injury as well as improving its function. The OGTT evidenced that this compound could promote the glucose tolerance of acute glucose increase in both diabetic and normal healthy rats.
authors.affiliation: Faculty of Pharmaceutical Sciences, Tongji Medical College of Huazhong University of Science and Technology, Hangkong Road 13#, Wuhan 430030, China.
authors.forename: Yonghui
authors.initials: Y
authors.lastname: Zhang
authors.forename: Jinyan
authors.initials: J
authors.lastname: Cai
authors.forename: Hanli
authors.initials: H
authors.lastname: Ruan
authors.forename: Huifang
authors.initials: H
authors.lastname: Pi
authors.forename: Jizhou
authors.initials: J
authors.lastname: Wu
mesh_terms: D015107:4-Butyrolactone / Q000031:analogs & derivatives; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002681:China; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D016166:Free Radical Scavengers / Q000494:pharmacology; D005951:Glucose Tolerance Test; D007004:Hypoglycemic Agents / Q000627:therapeutic use* / Q000633:toxicity; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D051379:Mice; D009005:Monosaccharides / Q000627:therapeutic use* / Q000633:toxicity; D009569:Nitric Oxide / Q000097:blood; D019001:Nitric Oxide Synthase / Q000097:blood; D029595:Orchidaceae / Q000737:chemistry*; D010179:Pancreas / Q000473:pathology; D008517:Phytotherapy; D051381:Rats; D017208:Rats, Wistar; D013482:Superoxide Dismutase / Q000097:blood
chemical_list: C422363:3-glucopyranosyloxybutanolide; D001786:Blood Glucose; D016166:Free Radical Scavengers; D007004:Hypoglycemic Agents; D009005:Monosaccharides; D009569:Nitric Oxide; D008315:Malondialdehyde; D019001:Nitric Oxide Synthase; D013482:Superoxide Dismutase; D015107:4-Butyrolactone